Insilico Medicine
英矽智能
End-to-end generative-AI drug discovery company, newly listed on HKEX, that both discovered and designed an oral IPF drug now heading to Phase III — with a parallel longevity/aging research agenda and an existing Gulf footprint.
- Location
- Hong Kong Science Park, Pak Shek Kok · Hong Kong
- Visit window
- Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
- Source status
- high confidenceprofiled
Next action
Keep the dossier ready and use the open questions if a visit window opens.
Why now: Visit window · Best Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
What they do
Runs an end-to-end 'AI + robotics + clinical' pipeline on its Pharma.AI platform (PandaOmics for targets, Chemistry42 for generative chemistry, inClinico for trial prediction). It has 40+ internal programs, 10+ at IND; lead asset rentosertib (ISM001-055) is an oral TNIK inhibitor for idiopathic pulmonary fibrosis.
Business model is platform-as-partner with large pharma.
Why it matters
Relationship/ecosystem + AI-platform benchmark, not a deal. Insilico is the most validated proof that generative AI can compress discovery R&D — the exact thesis Pure Advance applies to microbial-strain/biocontrol discovery — and is structurally pro-GCC (Abu Dhabi/Masdar office, Aramco-backed Prosperity7 investor, Saudi MISA MoU), so a Saudi founder is on-strategy.
The CEO's public aging-research agenda is a secondary bridge to a Coolvex consumer-health narrative.
Visit objective & route
A courtesy HK Science Park / founder-to-founder ecosystem visit to seed a relationship around the Saudi/GCC localization agenda and the AI-accelerated-discovery playbook — not a licensing pitch.
Approach route
Warm intro via the HKSTP incubator or a mutual GCC-investor contact (preferable to cold inbound BD); courtesy Science Park visit, confirm a host is in HK with a virtual-intro fallback.
Talking points
- Could we arrange a brief intro during our Hong Kong week?
- How do you engage external programs — Pharma.AI / PandaOmics access or co-discovery?
- Your Abu Dhabi (Masdar) office suggests a GCC track — is a Saudi collaboration of interest?
- Is a founder-to-founder / ecosystem intro more appropriate than a formal BD meeting?
- Bring: Pure Advance one-pager (AI-accelerated microbial biocontrols)
- Bring: 3-minute intro pitch and an NDA template for any confidential detail
Open questions
- Whether a senior HK/Asia lead is physically in Hong Kong during the visit window (execs travel heavily) — have a virtual-intro fallback.
- Active visitor entrance within HK Science Park.
- Whether a Riyadh 'discovery cell' is actually funded/announced (unverified — do not claim).
- Whether the HK Science Park unit hosts any wet-lab / robotics capability vs a corporate/representative office.
Risks & unknowns
- A public, multi-billion-deal company — they will not license from Pure Advance; do not frame outreach as a transaction. Realistic value is relationship + ecosystem.
- They engage at sovereign-fund / ministry / national-cluster scale; a Riyadh 'discovery cell' is unconfirmed intent — do not assert it as established.
Public sources
Private-pack boundary